Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report

Table 1 Medications administered during hospitalisation

Drug name	Usage, dosage, and route of administration	Therapy duration
Camrelizumab	200 mg ivgtt qd	June 8, 2022
	200 mg ivgtt qd	June 29, 2022
Hydrotalcite chewable tablets	0.5 g po tid	July 22, 2022 - August 1, 2022
Methylprednisolone sodium Succinate injection	80 mg iv qd	July 21, 2022 - July 27, 2022
	80 mg iv mos	July 22, 2022
	80 mg iv mos	July 23, 2022
	60 mg iv mos	July 24, 2022
	60 mg iv mos	July 25, 2022
	40 mg iv mos	July 26, 2022
	20 mg iv mos	July 27, 2022
Dexamethasone sodium phosphate injection	18 mg ivgtt mos	July 28, 2022
	15 mg ivgtt mos	July 29, 2022
	15 mg ivgtt mos	July 30, 2022
	11.25 mg ivgtt mos	July 31, 2022
	11.25 mg ivgtt mos	August 1, 2022
Methylprednisolone	po qd	Discharge medication